Kumar, S K
LaPlant, B
Roy, V
Reeder, C B
Lacy, M Q
Gertz, M A
Laumann, K
Thompson, M A
Witzig, T E
Buadi, F K
Rivera, C E
Mikhael, J R
Bergsagel, P L
Kapoor, P
Hwa, L
Fonseca, R
Stewart, A K
Chanan-Khan, A
Rajkumar, S V
Dispenzieri, A
Article History
Received: 1 July 2015
Accepted: 6 July 2015
First Online: 14 August 2015
Competing interests
: SKK obtained research support for clinical trials from Celgene, Millennium, Novartis, Janssen, Sanofi. JRM obtained research funding from Onyx Celgene Abbvie and Sanofi. PLB worked as consultant for Amgen, Mundipharma, Sanofi-Aventis, Janssen. He obtained research support from Novartis, Constellation Pharmaceuticals. PK obtained research support for clinical trials from Onyx. RF received consulting fees from Celgene, Genzyme, BMS, Bayer, Lilly, Onyx, Binding Site, Novartis, Sanofi, Millennium and AMGEN. He also has sponsored research from Onyx. He is also a member of the Scientific Advisory Board of Applied Biosciences. AKS worked as consultant for Celgene, Janssen, Novartis. AD obtained research support for clinical trials from Pfizer, Jannsen, Millenium, Alnylam, and Celgene. The remaining authors declare no conflict of interest.